Sector News

Chiltern PCR buy cements Asia-Pacific offering

September 30, 2014
Life sciences
Chiltern has made its second significant acquisition this year snapping up fellow contract research organisation Pacific Clinical Research in a move designed to secure a stronger foothold in the Asia-Pacific region.
 
The London, UK and Wilmington, NC-based group says the addition of PCR will allow it to offer integrated services throughout the Asia-Pacific (APAC) region and strengthens in particular its offering within oncology and anti-infective areas.
 
Chiltern has been considering a means of growing capabilities in APAC for some time, because there is great interest across the industry to place more clinical trials in the region, a company spokesman told PharmaTimes.
 
“We are seeing APAC regularly in RFIs [request for information] and RFPs [request for proposal] from current and prospective customers, so this puts us in a more competitive position as a truly global service provider”, he explained. 
 
Terms of the acquisition, which follows Chiltern’s summer purchase of specialist oncology and resourcing CRO Ockham, are being kept under wraps.
 
The firm now has over 2,200 staff working across 45 countries and while no other strategic changes are immediately expected, “we are always looking for ways to improve our business and will consider other opportunities that align with the needs of our customers,” the spokesman said.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

October 17, 2021

Colorcon acquires a majority share in Ideal Cures Pvt. Ltd., India

Life sciences

Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.

October 17, 2021

Barriers exist, but participation urgent in breast cancer clinical trials: report

Life sciences

Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.

October 17, 2021

Danish consortium acquires part of Jernbanebyen to create one of the world’s healthiest urban villages

Life sciences

The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world. 

Send this to a friend